Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop
Chana Weinstock(United States Food and Drug Administration), Julia A. Beaver(Center for Drug Evaluation and Research), John Baxley(United States Food and Drug Administration), Jim C. Hu(Presbyterian Hospital), Brian I. Rini(Vanderbilt University Medical Center), Charles J. Viviano(United States Food and Drug Administration), Martin T. King(Brigham and Women's Hospital), Danil V. Makarov(VA NY Harbor Healthcare System), Peter A. Pinto(National Institutes of Health), Daniel L. Suzman(United States Food and Drug Administration), Maha Hussain(Northwestern University), Howard M. Sandler(Cedars-Sinai Medical Center), Raejshwari Sridhara(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Daniel Y. Song(Johns Hopkins University), Paul G. Kluetz(United States Food and Drug Administration), Peter R. Carroll(University of California, San Francisco), Scott E. Eggener(University of California, Los Angeles), Peter N. Schlegel(EcoHealth Alliance), Kirsten B. Goldberg(United States Food and Drug Administration), Mack Roach(University of California, San Francisco), Terry Kungel, Ke Liu(Chinese Academy of Sciences), Eric A. Klein(Meta (United States)), Jonathan P. Jarow(Center for Drug Evaluation and Research), Amna Ibrahim(Beni-Suef University)
Cited by 14
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k